New combo therapy shows promise for Hard-to-Treat cancers

This study tests three drugs—durvalumab, olaparib, and cediranib—in different combinations for people with advanced solid tumors, including ovarian, breast, lung, prostate, and colorectal cancers. The goal is to see if these combinations can shrink tumors or slow cancer growth. Participants receive the drugs through an IV or as pills, and the study tracks side effects and how well the treatment works. This is not a cure, but aims to control the disease.